One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation
PavelOsmancikMD, PhDaDaliborHermanMD, PhDaPetrNeuzilMD, CScbPavelHalaMDbMilosTaborskyMD, CSccPetrKalaMD, PhDdMartinPoloczekMDdJosefStasekMD, PhDeLudekHamanMD, PhDeMarianBrannyMD, PhDfJanChovancikMDfPavelCervinkaMD, PhDgJiriHolyMDgTomasKovarnikMD, PhDhDavidZemanekMD, PhDhStepanHavranekMD, PhDhVlastimilVancuraMD, PhDiPetrPeichlMD, PhDj…Vivek Y.ReddyMDbl∗
doi : 10.1016/j.jacc.2021.10.023
Volume 79, Issue 1, 4–11 January 2022, Pages 1-14
The PRAGUE-17 (Left Atrial Appendage Closure vs Novel Anticoagulation Agents in Atrial Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) was noninferior to nonwarfarin direct oral anticoagulants (DOACs) for preventing major neurological, cardiovascular, or bleeding events in patients with atrial fibrillation (AF) who were at high risk.
Does Percutaneous Left Atrial Appendage Closure Stand the Test of Time?∗
Faisal M.MerchantMD
doi : 10.1016/j.jacc.2021.10.022
Volume 79, Issue 1, 4–11 January 2022, Pages 15-17
Reintervention and Survival After Transcatheter Pulmonary Valve Replacement
Doff B.McElhinneyMDaYulinZhangPhDaDaniel S.LeviMDbStanimirGeorgievMDcElżbieta KatarzynaBiernackaMD, PhDdBryan H.GoldsteinMDeShabanaShahanavazMDfAthar M.QureshiMDgAllison K.CabalkaMDhHollyBauser-HeatonMD, PhDiAlejandro J.TorresMDjBrian H.MorrayMDkAimee K.ArmstrongMDlOscarMillan-IturbeMDm∗Lynn F.PengMDaJamil A.AboulhosnMDnWitoldRużyłłoMD, PhDdFelixBergerMDo…StephanSchubertMDo†‡
doi : 10.1016/j.jacc.2021.10.031
Volume 79, Issue 1, 4–11 January 2022, Pages 18-32
Transcatheter pulmonary valve (TPV) replacement (TPVR) has become the standard therapy for postoperative pulmonary outflow tract dysfunction in patients with a prosthetic conduit/valve, but there is limited information about risk factors for death or reintervention after this procedure.
Outcome After Transcatheter Pulmonary Valve Replacement: Are We Focusing on the Long Term Now?∗
AlainFraisseMD, PhDabAlexanderKempnyMD, PhDacCarlesBautista-RodriguezMD, PhDab
doi : 10.1016/j.jacc.2021.10.032
Volume 79, Issue 1, 4–11 January 2022, Pages 33-34
Intramyocardial Hemorrhage and the “Wave Front� of Reperfusion Injury Compromising Myocardial Salvage
TingLiuMD, PhDab∗Andrew G.HowarthMD, PhDac∗YinyinChenMD, PhDadAnand R.NairPhDaHsin-JungYangPhDaDaoyuanRenMDdRichardTangMDaJaneSykesBSeMichael S.KovacsPhDeDaminiDeyPhDaPiotrSlomkaPhDaJohn C.WoodMD, PhDfRobertFinneyPhDgMengsuZengMD, PhDdFrank S.PratoPhDeJosephFrancisPhDhDaniel S.BermanMDaPrediman K.ShahMDa…RohanDharmakumarPhDaj
doi : 10.1016/j.jacc.2021.10.034
Volume 79, Issue 1, 4–11 January 2022, Pages 35-48
Reperfusion therapy for acute myocardial infarction (MI) is lifesaving. However, the benefit of reperfusion therapy can be paradoxically diminished by reperfusion injury, which can increase MI size.
Intramyocardial Hemorrhage: The Final Frontier for Preventing Heart Failure Post-Myocardial Infarction∗
ColinBerryMBChB, PhDabBorjaIbáñezMD, PhDc
doi : 10.1016/j.jacc.2021.11.002
Volume 79, Issue 1, 4–11 January 2022, Pages 49-51
Maternal Cardiac Function at Midgestation and Development of Preeclampsia
ElenaGibboneMDaIuliaHulutaMDaAlanWrightPhDbKypros H.NicolaidesMDaMariettaCharakidaMD, PhDac
doi : 10.1016/j.jacc.2021.10.033
Volume 79, Issue 1, 4–11 January 2022, Pages 52-62
Preeclampsia (PE) is an independent risk factor for adverse maternal cardiovascular outcomes. The role of maternal cardiac function in the pathophysiology of PE remains unclear.
Cardiovascular Indexes in the Era of Preeclampsia: Prevention or Long-Term Outcome Prediction?∗
Karen L.FlorioDO, MPHabAnnaGrodzinskyMD, MScbc
doi : 10.1016/j.jacc.2021.11.003
Volume 79, Issue 1, 4–11 January 2022, Pages 63-65
Coronary Atherosclerotic Plaque Regression: JACC State-of-the-Art Review
Luke P.DawsonMBBS, MPHabcdMarkLumMBBSbNiteshNerlekerMBBS, PhDbefStephen J.NichollsMBBS, PhDbeJamieLaylandMBChB, PhDab
doi : 10.1016/j.jacc.2021.10.035
Volume 79, Issue 1, 4–11 January 2022, Pages 66-82
Over the last 3 decades there have been substantial improvements in treatments aimed at reducing cardiovascular (CV) events. As these treatments have been developed, there have been parallel improvements in coronary imaging modalities that can assess plaque volumes and composition, using both invasive and noninvasive techniques. Plaque progression can be seen to precede CV events, and therefore, many studies have longitudinally assessed changes in plaque characteristics in response to various treatments, aiming to demonstrate plaque regression and improvements in high-risk features, with the rationale being that this will reduce CV events. In the past, decisions surrounding treatments for atherosclerosis have been informed by population-based risk scores for initiation in primary prevention and low-density lipoprotein cholesterol levels for titration in secondary prevention. If outcome data linking plaque regression to reduced CV events emerge, it may become possible to directly image plaque treatment response to guide management decisions.
Mortality and Postdischarge Acute Care Utilization for Cardiovascular Conditions at Safety-Net Versus Non–Safety-Net Hospitals
MichaelLiuMPhilabJose F.FigueroaMD, MPHcYangSongMScaRishi K.WadheraMD, MPP, MPhila
doi : 10.1016/j.jacc.2021.10.006
Volume 79, Issue 1, 4–11 January 2022, Pages 83-87
Staphylococcus Aureus Infective Endocarditis: JACC Patient Pathways
JuliaGrapsaMD, PhDaChristopherBlauthBSc, MB BSaY.S.ChandrashekharMDbBernardPrendergastMD, PhDaBlairErbJr.MDcMichaelMackMDdValentinFusterMD, PhDef
doi : 10.1016/j.jacc.2021.10.015
Volume 79, Issue 1, 4–11 January 2022, Pages 88-99
A 19-year-old female patient presented with Staphylococcus aureus infective endocarditis, with suspected subdural brain hemorrhage, disseminated intravascular coagulopathy, and septic renal as well as spleen infarcts. The patient had extensive vegetations on the mitral and tricuspid valves and underwent urgent mitral and tricuspid repair. This paper discusses the clinical case and current evidence regarding the management and treatment of Staphylococcus aureus endocarditis.
Association Between Metoprolol and Prognosis of COVID-19Â Patients
XinpingChenPhDShengmiaoFuMMWeihuaXuMM
doi : 10.1016/j.jacc.2021.09.1383
Volume 79, Issue 1, 4–11 January 2022, Page e7
More Analysis Needed to Minimize Confounding
Cheng-YiWangMDChing-YiChenMDChih-ChengLaiMD
doi : 10.1016/j.jacc.2021.09.1385
Volume 79, Issue 1, 4–11 January 2022, Page e9
Beta-Blockers in COVID-ARDS: Inflammation or Hemodynamic?
Charlesde RoquetailladeMD, PhDJérémieGuilleminMD, MSVictorBeaucotéMD, MSRomainBarthelemyMD, MSBenjamin GlennChoustermanMD, PhD
doi : 10.1016/j.jacc.2021.09.1384
Volume 79, Issue 1, 4–11 January 2022, Page e11
Reply: Biological Plausibility Behind the Benefits of Intravenous Metoprolol in Severe COVID-19
ArnoldoSantosMD PhDJuanMartÃnez-MillaMD, PhDCésarPérez-CalvoMD, PhDBorjaIbáñezMD, PhD
doi : 10.1016/j.jacc.2021.10.030
Volume 79, Issue 1, 4–11 January 2022, Pages e13-e14
